

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/40</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/50033</b> <b>(43) International Publication Date:</b> 12 November 1998 (12.11.98)
<b>(21) International Application Number:</b> PCT/IB98/00662 <b>(22) International Filing Date:</b> 1 May 1998 (01.05.98) <b>(30) Priority Data:</b> 60/045,635 5 May 1997 (05.05.97) US <b>(71) Applicant (for all designated States except US):</b> PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LUNDY, Kristin, Marie [US/US]; Apartment 631, 600 Meridian Street, Groton, CT 06340 (US). RICKETTS, Anthony, Paul [GB/US]; 1306 Pequot Trail, Stonington, CT 06378 (US). <b>(74) Agents:</b> SPIEGEL, Allen, J.; c/o Mark Charles Green, Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH (GB) et al.		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND INFLAMMATION IN DOGS		
<b>(57) Abstract</b>  Treating or preventing inflammatory processes and diseases in dogs associated with the activity of inducible cyclo-oxygenase-2 (COX-2), while at the same time reducing or eliminating undesirable side effects associated with simultaneous inhibition of the activity of constitutive cyclo-oxygenase-1 (COX-1) by selectively inhibiting COX-2 activity with reference to COX-1 activity, wherein the selectivity ratio or COX-2 : COX-1 activity inhibition is at least 3 : 1 based on <i>ex vivo</i> inhibition levels measured in whole blood; the inhibitor is a member selected from the group of anti-inflammatory compounds consisting essentially of salicylic acid derivatives, <i>p</i> -aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids, enolic acids, and alkanones; the inhibitor in particular is comprised of (+)( <i>S</i> )-enantiomer of 6-chloro- $\alpha$ -methyl-9 <i>H</i> -carbazole-2-acetic acid.		